Skip to Content

Fidelity Select Pharmaceuticals Port FPHAX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 27.98  /  +0.04 %
  • Total Assets 1.1 Bil
  • Adj. Expense Ratio
    0.760%
  • Expense Ratio 0.760%
  • Distribution Fee Level Low
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.50%
  • Turnover 45%

USD | NAV as of Mar 28, 2024 | 1-Day Return as of Mar 28, 2024, 10:12 PM GMT+0

Morningstar’s Analysis FPHAX

Will FPHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Select Pharmaceuticals Port’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Silver.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FPHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 70.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

23.39 217.7 Mil
Healthcare

Novo Nordisk A/S ADR

14.64 136.3 Mil
Healthcare

AstraZeneca PLC ADR

8.45 78.6 Mil
Healthcare

Merck & Co Inc

5.14 47.9 Mil
Healthcare

GSK PLC ADR

4.83 45.0 Mil
Healthcare

UCB SA

3.51 32.7 Mil
Healthcare

Gilead Sciences Inc

3.12 29.0 Mil
Healthcare

Royalty Pharma PLC Class A

2.79 25.9 Mil
Healthcare

Merck KGaA

2.27 21.1 Mil
Healthcare

Moderna Inc

2.23 20.8 Mil
Healthcare